Intellia Therapeutics, Inc (NTLA) Stock Rating

Intellia Therapeutics is a gene-editing company developing CRISPR/Cas9-based therapeutics. CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9) is a technology for precisely altering specific genomic DNA sequences, and Intellia applies it to treat genetically defined diseases.

Rating as of 2026-07-06. Live price updates in real time.